NANOBIOTIX news, videos and press releases - Page 3
For more news please use our advanced search feature.
NANOBIOTIX - More news...
NANOBIOTIX - More news...
- NANOBIOTIX Voting Rights and Shares Capital of the Company
- NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
- NANOBIOTIX to Present at the Jefferies London Healthcare Conference
- NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
- NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
- Nanobiotix: Voting Rights and Shares Capital of the Company
- Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
- Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
- Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
- Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
- Nanobiotix: Voting Rights and Shares Capital of the Company
- NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
- NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
- Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
- NANOBIOTIX: Voting Rights and Shares Capital of the Company
- Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
- Nanobiotix: Voting Rights and Shares Capital of the Company
- NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
- NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
- NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
- CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
- NANOBIOTIX Provides First Quarter Operational and Financial Update
- NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
- NANOBIOTIX to Participate in Two Upcoming Investor Conferences
- Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
- NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
- New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
- NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
- NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
- Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
